Q: Please give your opinion if you believe management that this company will not be able to continue as going concern if acquisition by Stryker is not approved by shareholders.
Best Regards
Harold
Best Regards
Harold
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Today's news: TSO3 being acquired at $0.43 a share. My average price is $0.38. What should I do? Sell limit order at $0.43, or...? Not sure how to get the full value out of my shares.
Thank you.
Thank you.
Q: Could you please give me your thoughts on TSO3 based on their last earnings?
Thank you very much.
Thank you very much.
Q: With TOS now at 0.36$, do you see a big upside potential and if so, is it worth the risk ?
Thanks
Thanks
Q: Hello 5i, what is your opinion on theses three companies for a 2-3 year hold? Would you invest in any of those? If not, do you have a better suggestion in the small cap area? Does not have to be in pharma/life science. Thanks for the great service!
Q: thoughts on TOS , results and news
Q: Can you weigh in on what this may do to TOS? I think a recent Q/A mentioned you liked it's upside. The market hated the announcement below and it would be great to hear why and if it is now a buy (market overreacted?)
25 Jan 2018 11:04 ET
11:04 AM EST, 01/25/2018 (MT Newswires) -- TSO3 Inc. (TOS.TO) has plunged 21% to a new 52-week low after announcing that it has entered into a new agreement with Getinge Infection Control AB, its global distribution partner since November 2015.
25 Jan 2018 11:04 ET
11:04 AM EST, 01/25/2018 (MT Newswires) -- TSO3 Inc. (TOS.TO) has plunged 21% to a new 52-week low after announcing that it has entered into a new agreement with Getinge Infection Control AB, its global distribution partner since November 2015.
Q: Hi Peter and team:
Two of the companies in my small cap portfolio, Acuity
Ads and TSO3, have performed badly for me in the last year. I am down 50% on AT and down 40% on TSO. I am willing to be patient but wondering if this is a recovery that could take many months, if not years, which is too long for me. Do I hang on, or are there other small cap stocks with promising technologies that may be preferable with a shorter timeline to success? By the way, I own PHO after reading your reviews, which has worked out well for me, thanks.
Pierre
Two of the companies in my small cap portfolio, Acuity
Ads and TSO3, have performed badly for me in the last year. I am down 50% on AT and down 40% on TSO. I am willing to be patient but wondering if this is a recovery that could take many months, if not years, which is too long for me. Do I hang on, or are there other small cap stocks with promising technologies that may be preferable with a shorter timeline to success? By the way, I own PHO after reading your reviews, which has worked out well for me, thanks.
Pierre
Q: Good morning,
Could you comment on the big drop in the stock price that is surely related to the Spruce Point Capital report on TOS, and your comments on the report? Thanks.
Could you comment on the big drop in the stock price that is surely related to the Spruce Point Capital report on TOS, and your comments on the report? Thanks.
Q: Could you give me your opinion on TOS3 earnings, and whether you would consider it a buy now. Thanks, Mark
Q: between tso3 and theretechnologies if you had to pick one which would it be and why. dave
Q: Hi,
What is your current view on this stock? thanks Clare
What is your current view on this stock? thanks Clare
Q: Hi Team, On May 8/17 I asked a general question on TOS and your answer was:TOS has done a very good job getting the company to where it is, with FDA approval, good partners and a solid growth opportunity worldwide. We like what it has done, and it has good potential. But.....the stock is very expensive and this needs consideration. It trades at 7X 'expected' 2018 sales already. It is expected to turn a profit in 2018 but any slowdown or problems would really hurt the stock. We would not 'assume' 40% returns here, but do like it generally today.
I have a followup question, how much of TOS's revenue would come from the US or Europe? My thinking is if TOS has a significant exposure to the US in particular this would help me make an investment decision. It appears to me today good companies with US exposure are worth a little special attention or premium. Thanks as always. Chris
I have a followup question, how much of TOS's revenue would come from the US or Europe? My thinking is if TOS has a significant exposure to the US in particular this would help me make an investment decision. It appears to me today good companies with US exposure are worth a little special attention or premium. Thanks as always. Chris
Q: Hi Team, Sorry about just copying this info, but RBC is doing a better job than I could:
12:23 PM EDT, 05/03/2017 (MT Newswires) -- RBC Capital is initiating coverage on TSO3 with an Outperform, Speculative Risk rating and C$4.25 target. TSO3 has recently commercialized a proprietary and highly differentiated device for the sterilization of medical devices, particularly endoscopes, in healthcare settings, the brokerage reports, adding that the company is therefore uniquely positioned with its marketing partner, Getinge (a world leader in infection control sales). "We expect greater than ~40% returns over the next 12-months."
Price: 3.17, Change: +0.08, Percent Change: +2.6
Would you agree or disagree with RBC on TSO3?
Thanks, Chris
12:23 PM EDT, 05/03/2017 (MT Newswires) -- RBC Capital is initiating coverage on TSO3 with an Outperform, Speculative Risk rating and C$4.25 target. TSO3 has recently commercialized a proprietary and highly differentiated device for the sterilization of medical devices, particularly endoscopes, in healthcare settings, the brokerage reports, adding that the company is therefore uniquely positioned with its marketing partner, Getinge (a world leader in infection control sales). "We expect greater than ~40% returns over the next 12-months."
Price: 3.17, Change: +0.08, Percent Change: +2.6
Would you agree or disagree with RBC on TSO3?
Thanks, Chris
Q: TOS recently released results with revenue up from 0.15 million to 3.75 with a loss of $0.02.
Revenue growth is massive (albeit from a very low number). Is this growth expected to continue? Where will/could this company be in 1 - 3 years? Any idea when they expect to have positive earnings?
I'm a holder (~1% of portfolio) and wondering if I should add. I personally like the technology and progress of the company thus far but continue to seek your input.
Revenue growth is massive (albeit from a very low number). Is this growth expected to continue? Where will/could this company be in 1 - 3 years? Any idea when they expect to have positive earnings?
I'm a holder (~1% of portfolio) and wondering if I should add. I personally like the technology and progress of the company thus far but continue to seek your input.
Q: Hello Team
What are your thoughts on TSO3 these days. The price is moving but how are their fundamentals
Thank You
Clarence
What are your thoughts on TSO3 these days. The price is moving but how are their fundamentals
Thank You
Clarence
Q: Do you have any comments on results released today? Why was the drop so significant? Volume 6x normal...
I'd still like to hold (maybe even add to) as they seem to have some interesting technology. Is this an opportunity to add for the long term? Current position is 1.2%, and I'm still in the green despite the drop.
C
I'd still like to hold (maybe even add to) as they seem to have some interesting technology. Is this an opportunity to add for the long term? Current position is 1.2%, and I'm still in the green despite the drop.
C
Q: Hi Peter;
please comment on TOS's earnings.
Thanks,
Ron
please comment on TOS's earnings.
Thanks,
Ron
Q: Hi my question is about Tso3. I am finally back above water after a few years. Should I buy more sell or hold. I'm fairly conservative and this was recommended by my ex broker. Thanks Al
Q: Any thoughts on today's FDA approval would be appreciated
Robert
Robert